Example: Heart Attack

Clinical Trials on Herpes Zoster

Total 345 results

NCT03903237

Completed

Herpes Zoster: Risk Factors, Complications and Special Situations

Conditions: Herpes Zoster
NCT02151240

Unknown status

Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection in Patients With Herpes Zoster

Conditions: Herpes Zoster
NCT04091451

Recruiting

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) Who Had Prior Episode of Shingles

Conditions: Herpes Zoster
NCT03016884

Active, not recruiting

Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients

Conditions: Herpes Zoster
NCT02979639

Completed

Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age

Conditions: Herpes Zoster
NCT04258930

Recruiting

Occlusion vs Standard Treatment for the Treatment of Herpes Zoster

Conditions: Herpes Zoster
NCT02690207

Completed

Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.

Conditions: Herpes Zoster
NCT03439657

Completed

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older

Conditions: Herpes Zoster
NCT04176939

Recruiting

A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response

Conditions: Herpes Zoster
NCT01573182

Completed

Herpes Zoster Vaccine for Bone Marrow Transplant Donors

Conditions: Herpes Zoster
NCT02735915

Completed

Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older

Conditions: Herpes Zoster
NCT02581410

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier

Conditions: Herpes Zoster
NCT03314103

Completed

Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age

Conditions: Herpes Zoster
NCT00526864

Completed

Measuring Herpes Zoster and PHN Associated Burden of Illness and Health Care Utilization Costs in Thailand

Conditions: Herpes Zoster
NCT02075515

Completed

Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age

Conditions: Herpes Zoster
NCT01827839

Completed

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster

Conditions: Herpes Zoster
NCT01295320

Completed

Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects

Conditions: Herpes Zoster
NCT01751165

Completed

Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older

Conditions: Herpes Zoster
NCT02045836

Completed

Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older

Conditions: Herpes Zoster
NCT01767467

Completed

Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers

Conditions: Herpes Zoster
NCT02052596

Completed

Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older

Conditions: Herpes Zoster
NCT02152800

Completed

A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster

Conditions: Herpes Zoster
NCT02058589

Completed

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal Transplant

Conditions: Herpes Zoster
NCT01798056

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy

Conditions: Herpes Zoster
NCT01954251

Completed

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

Conditions: Herpes Zoster